RALEIGH–LipoScience Inc. said it has closed its Series E financing at $15 million.

Investors in the round include Three Arch Partners, U.S. Bancorp Piper Jaffray Ventures, G.E. Capital Equity Investments, INVESCO Private Capital, and Raleigh-based A.M. Pappas & Associates.

Richard O. Brajer, president and chief executive officer of LipoScience said, “This is a giant step forward–and will allow us to confidently invest in the business and build awareness of our flagship product, the NMR LipoProfile.”

The company introduced the NMR LipoProfile, which analyzes a patient’s lipoprotein number and size using nuclear magnetic resonance spectroscopy. Lipoprotein particles are the tiny spheres that transport cholesterol through the body.

The LipoProfile provides unique information about the particles that gives doctors a much better indication of heart disease risk than traditional methods of measuring cholesterol.

Founded in 1994, LipoScience develops and markets new clinical applications of NMR spectroscopy for cardiovascular and metabolic disorders to doctors, commercial diagnostic laboratories and clinical research clients.